- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02497755
Connection to Care: Pilot Study of a Mobile Health Tool for Patients With Depression and Anxiety
October 25, 2017 updated by: Amy Bauer, University of Washington
This is a pilot feasibility study of a mobile health tool (smartphone app) for primary care patients receiving treatment for depression or anxiety delivered in an integrated primary care-based behavioral health program.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This research is a feasibility pilot study of a smartphone app using mixed methods.
The research seeks to answer the question: "Is a mobile health tool for patient self-management feasible, useful, appropriate, and acceptable for patients and care managers for patients with depression or anxiety treated in an integrated primary-care based behavioral health program?"
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98105
- University of Washington Neighborhood Clinic, Ravenna
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be part of the Behavioral Health Integration Program for anxiety and/or depression; Must have an iPhone or Android smartphone with a mobile voice calling plan with a US carrier; Fluent in English
Exclusion Criteria:
- Individual unable or unwilling to accept the terms of the Ginger.io terms of Use; Actively suicidal as determined by a healthcare professional; score of 3 on the Patient Health Questionnaire-9 item 9 (which assesses thoughts of self-harm); or documented history of 2 or more prior suicide attempts; Working diagnosis of psychotic disorder, bipolar disorder, dementia, active substance dependence
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mobile app
Participants will install an app on their smartphone to add to their treatment for depression and/or anxiety.
|
A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
App Acceptability as Measured by Number of Patient App Users Who Rate App Easy to Use and Time Spent Reasonable
Time Frame: Four weeks after intervention started
|
The number of patients who rated the app was easy to use and the amount of time spent using the app as reasonable when asked about app acceptability in a qualitative interview and via a quantitative survey.
Specific survey items included "The technology requires little effort to use," "The technology was easy to learn how to use," "The Ginger.io
app is easy to use," and "The time required to answer questions in the Ginger.io
app is reasonable."
All patients who expressed agreement ("Somewhat Agree," "Agree," or "Strongly Agree") to these items and to similar questions in the qualitative interview were included in the count of patients who found the app acceptable.
|
Four weeks after intervention started
|
App Acceptability as Measured by Number of Care Manager Dashboard Users Who Rate Dashboard Easy to Use and Time Spent Reasonable
Time Frame: 8-16 weeks after final patient participant is enrolled
|
The number of care managers who agreed that the app dashboard was easy to use and that the amount of time spent using the app dashboard was reasonable when asked about app acceptability and benefit vs. burden of use with regard to clinical workflow in a qualitative interview.
|
8-16 weeks after final patient participant is enrolled
|
App Usefulness as Measured by Number of Patient App Users Who Rate App as Useful
Time Frame: Four weeks after intervention started
|
The number of patients who rated the app as useful to them when asked about app usefulness in a qualitative interview and via a quantitative survey.
Specific survey items included "This technology is useful."
All patients who expressed agreement ("Somewhat Agree," "Agree," or "Strongly Agree") to this items and to similar questions in the qualitative interview were included in the count of patients who found the app acceptable.
|
Four weeks after intervention started
|
App Usefulness as Measured by Number of Care Manager Dashboard Users Who Rate Dashboard as Useful
Time Frame: 8-16 weeks after final patient participant is enrolled
|
The number of care managers who expressed that the app was useful to them with regard to clinical workflow in a qualitative interview.
|
8-16 weeks after final patient participant is enrolled
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technology Acceptability as Measured by the Obtrusiveness Scale for Pervasive Technology (Modified)
Time Frame: During weeks 3 and 8
|
The mean total of patient app users' responses to the modified version of the Obtrusiveness Scale for Pervasive Technology, with a mean score of 13-39 indicating that the app is generally perceived as unacceptable/obtrusive, 40-64 indicating neutrality, and 65-91 indicating that the app is generally perceived as acceptable/unobtrusive.
|
During weeks 3 and 8
|
Patient Satisfaction as Measured by the Ginger.io Product Feedback Survey.
Time Frame: Days 30, 56
|
The mean total of patient app users' responses to the Ginger.io
product feedback survey, with a mean score of 7-21 indicating satisfaction with the app, 22-34 neutrality, and 35-49 expressing dissatisfaction.
|
Days 30, 56
|
Patient Use of the App as Measured by Percentage of App Surveys Completed.
Time Frame: Eight weeks after intervention started
|
The mean percentage of surveys presented to users through the app that were completed by patient app users in their first 8 weeks of using the app.
App survey questions included weekly PHQ-9 and GAD-7 scales and daily measures of mood and medication use as well as satisfaction surveys.
|
Eight weeks after intervention started
|
Care Team Communication as Measured by the Consumer Assessment of Healthcare Providers and Systems (CAHPS) - Communication Scale
Time Frame: Weeks 4 and 8
|
The mean total of patient app users' responses to the 6 items in the Consumer Assessment of Healthcare Providers and Systems (CAHPS) - Communication scale, with a mean score of 0-5 indicating that participants never or almost never experienced good communication with their care team, 6-11 indicating that participants sometimes experienced good communication with their care team, 12-17 indicating that patients usually experienced good communication with their care teams, and a score of 24 indicating that patients always experienced good communication with their care team.
|
Weeks 4 and 8
|
Care Process Measures as Measured by the Number and Type of Contacts With Care Manager.
Time Frame: Eight weeks after intervention started
|
The mean number of Follow-Up contacts between patient and care manager during the 8 weeks following the patient's activation of the app.
(Other types of contacts with the care manager include Initial Assessment and Contact Attempt, but neither of these occurred during the time frame of app use.)
|
Eight weeks after intervention started
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Amy M Bauer, MD, MS, University of Washington
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2015
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
February 14, 2015
First Submitted That Met QC Criteria
July 13, 2015
First Posted (Estimate)
July 14, 2015
Study Record Updates
Last Update Posted (Actual)
December 2, 2017
Last Update Submitted That Met QC Criteria
October 25, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 47871
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Lawson Health Research InstituteTerminated
Clinical Trials on smartphone
-
Jordan University of Science and TechnologyNot yet recruitingUrinary IncontinenceJordan
-
University of OklahomaWithdrawnRisk Reduction Behavior
-
Kibi International UniversityCompleted
-
University Hospital, MontpellierCompleted
-
Linkoeping UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnMalignant Solid Neoplasm | Sarcoma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Central Nervous System NeoplasmUnited States
-
Goalspal LLCRecruitingParkinson DiseaseUnited States
-
NHS Greater Glasgow and ClydeNot yet recruitingMemory Impairment | Stroke (CVA) or TIA
-
Gunma UniversityCompletedSubthreshold DepressionJapan
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; American...RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States